News headlines about Boston Scientific (NYSE:BSX) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Boston Scientific earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 46.0196241776723 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s analysis:
- $2.35 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter (americanbankingnews.com)
- Boston Scientific (BSX) Given a $33.00 Price Target at SunTrust Banks (americanbankingnews.com)
- Boston Scientific’s (BSX) Robust Earnings Growth Keep it a Buy (investorplace.com)
- Boston Scientific Corporation (BSX) Expected to Announce Earnings of $0.34 Per Share (americanbankingnews.com)
- Illiquidity and stock returns: Boston Scientific Corporation (NYSE:BSX) – Market Breaking Point (press release) (journalfinance.net)
Shares of Boston Scientific (NYSE:BSX) traded down $0.20 during mid-day trading on Thursday, reaching $25.04. The company had a trading volume of 9,674,608 shares, compared to its average volume of 6,979,998. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The stock has a market capitalization of $34,247.51, a PE ratio of 20.44, a P/E/G ratio of 1.92 and a beta of 0.96. Boston Scientific has a 52 week low of $20.37 and a 52 week high of $29.93.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting the consensus estimate of $0.31. The company had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. Boston Scientific’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the business earned $0.27 earnings per share. research analysts anticipate that Boston Scientific will post 1.25 EPS for the current year.
A number of research firms recently commented on BSX. Oppenheimer reaffirmed a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 29th. BMO Capital Markets reaffirmed a “buy” rating and set a $31.00 target price on shares of Boston Scientific in a report on Wednesday, November 29th. BTIG Research raised Boston Scientific from a “neutral” rating to a “buy” rating and set a $31.00 target price for the company in a report on Thursday, November 30th. SunTrust Banks set a $33.00 target price on Boston Scientific and gave the stock a “buy” rating in a report on Monday. Finally, Cowen set a $31.00 target price on Boston Scientific and gave the stock a “buy” rating in a report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company. Boston Scientific currently has an average rating of “Buy” and a consensus target price of $30.97.
In other news, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $28.72, for a total value of $445,160.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Supratim Bose sold 347,137 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total value of $10,108,629.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 424,698 shares of company stock valued at $12,273,553. 0.74% of the stock is owned by company insiders.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.